Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients

Abstract

Objective Covid‐19 can involve multiple organs including the nervous system. We sought to characterize the neurologic manifestations, their risk factors, and associated outcomes in hospitalized patients with Covid‐19. Methods We examined neurologic manifestations in 509 consecutive patients admitted with confirmed Covid‐19 within a hospital network in Chicago, Illinois. We compared the severity of Covid‐19 and outcomes in patients with and without neurologic manifestations. We also identified independent predictors of any neurologic manifestations, encephalopathy, and functional outcome using binary logistic regression. Results Neurologic manifestations were present at Covid‐19 onset in 215 (42.2%), at hospitalization in 319 (62.7%), and at any time during the disease course in 419 patients (82.3%). The most frequent neurologic manifestations were myalgias (44.8%), headaches (37.7%), encephalopathy (31.8%), dizziness (29.7%), dysgeusia (15.9%), and anosmia (11.4%). Strokes, movement disorders, motor and sensory deficits, ataxia, and seizures were uncommon (0.2 to 1.4% of patients each). Severe respiratory disease requiring mechanical ventilation occurred in 134 patients (26.3%). Independent risk factors for developing any neurologic manifestation were severe Covid‐19 (OR 4.02; 95% CI 2.04–8.89; P < 0.001) and younger age (OR 0.982; 95% CI 0.968–0.996; P = 0.014). Of all patients, 362 (71.1%) had a favorable functional outcome at discharge (modified Rankin Scale 0–2). However, encephalopathy was independently associated with worse functional outcome (OR 0.22; 95% CI 0.11–0.42; P < 0.001) and higher mortality within 30 days of hospitalization (35 [21.7%] vs. 11 [3.2%] patients; P < 0.001). Interpretation Neurologic manifestations occur in most hospitalized Covid‐19 patients. Encephalopathy was associated with increased morbidity and mortality, independent of respiratory disease severity.

Cited by papers we hold 12

• A review of cytokine-based pathophysiology of Long COVID symptoms · 2023
  No notice
• Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review · 2022
  Not checked
• Pathogenesis of Alzheimer’s Disease · 2022
  No notice
• Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates · 2022
  No notice
• Specialty Grand Challenge for Brain Disease Mechanisms · 2021
  Not checked
• Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) · 2021
  No notice
• High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms · 2021
  No notice
• Contrasting SARS-CoV-2 RNA copies and clinical symptoms in a large cohort of Colombian patients during the first wave of the COVID-19 pandemic · 2021
  Not checked
• Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up · 2021
  No notice
• Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium · 2021
  No notice
• Long-Lasting Cognitive Abnormalities after COVID-19 · 2021
  No notice
• Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers” · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.